Deven Choksey's research report on Tatva Chintan Pharma Chem
Consolidated revenue increased by 10.8% YoY (+8.3% QoQ) to INR 1,169 Mn., stood below our estimates (-4.3%), led by lower traction across the PTC (Phase Transfer Catalyst) and the PASC (Pharmaceutical and Agrochemical intermediates) segment, partially offset by stronger momentum in the SDA (Structure Directing Agents) segment. The double-digit revenue growth was driven by broad based growth across all the segments.
Outlook
We have rolled forward our valuation to Jun’27 estimates. We value Tatva Chintan at 40.0x Jun’27 EPS, implying a target price of INR 860. Tatva Chintan is currently trading at 65.8x/34.2x of our FY26E/FY27E EPS estimates. We downgrade our rating from “HOLD” to “SELL” as we believe all positive factors are fully priced in.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
